Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Turkey / NCT06646770
Starting soon Not applicable

SEgmentectomy Versus Lobectomy in T1C Non-Small Cell Lung Cancer (SELTIC)

NCT06646770 · tracked via the Priya Life Science Turkey tracker
Sponsor
Istanbul University - Cerrahpasa
Phase
Not applicable
Started
2025-01-02
Last updated
2024-10-17

Condition(s) studied

Non-Small Cell Lung Cancer

Investigational drug(s) / intervention(s)

SegmentectomyLobectomy

Segmentectomy: Pulmonary anatomic segmentectomy with mediastinal nodal dissection via VATS, RATS or open approach.

Lobectomy: Pulmonary lobectomy with mediastinal nodal dissection via VATS, RATS or open approach.

Study summary

The goal of this clinical trial is to investigate the role of segmentectomy in clinical T1c (2-3 cm) non-small cell lung cancer (NSCLC). The main questions we aim to answer are:

1. Is segmentectomy non-inferior to lobectomy in cT1c NSCLC in terms of overall and recurrence free survival?
2. What are the mortality and morbidity rates of segmentectomy compared to lobectomy?

Researchers will compare segmentectomy and lobectomy in terms of overall and recurrence free survival.

Participants will:

* Undergo either pulmonary lobectomy or segmentectomy with mediastinal nodal dissection
* Be followed up with a chest CT in every 3 months in first year, every 6 months in second year and every year for following 3 years

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Clinical T1c NSCLC * Parenchymal nodule \>2 cm in diameter * Parenchymal nodule ≤3 cm in diameter * Consolidation / Tumor Rate (CTR) ≥ 0.50 * Definitive pathological diagnosis of NSCLC preoperative or intraoperatively * No evidence of distant metastasis * No evidence of N2 disease * Adequate pulmonary functions for lobectomy or segmentectomy Exclusion Criteria: * Pure GGO lesions * Pathologic diagnosis other than NSCLC * Technically not suitable for simple or complex segmentectomy, or lobectomy * Evidence of distant metastasis * Pathologically confirmed N2 or N3 disease * Major comorbidity that precludes surgery * Intraoperative mediastinal nodal dissection of less than 3 lymph node stations * Prior malignancy in five years

Primary outcome measure(s)

  • Survival Survival — 5 years
    Overall and recurrence free survival

Trial sites (1)

FacilityCityRegionStatus
Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty Istanbul Turkey (Türkiye)

More Istanbul University - Cerrahpasa trials in Turkey

Postoperative Residual Neuromuscular Block and Passive Smoke Exposure in Pediatric Dental Patients Starting soon
Evaluation of Upper Extremity Functions in Obesity Hypoventilation Syndrome Patients Starting soon
Evaluation of the Effectiveness of the Pecha Kucha-Supported Microteaching Method in Nursing Process Education Active, not recruiting
Effect of Health Promotion Model-Based Oculomotor Exercise Program on Sleep Quality in Older Adults Starting soon
Validity and Reliability of the Exergame Enjoyment Questionnaire (EEQ) in Turkish Starting soon

Other trials for the same condition

Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104). Active, not recruiting
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015) Recruiting
Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer Active, not recruiting
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% Recruiting
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06646770 on ClinicalTrials.gov ↗ ← All trials in Turkey